Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy- United Kingdom

doi 10.3851/imp3166

Full Text

Abstract

Available in

Date

Authors

Publisher

International Medical Press

Related search

Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Infection and Drug Resistance
Infectious DiseasesPharmacology
2019English

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2013English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Efficacy of Bimin Decoction for Patients With Perennial Allergic Rhinitis: An Open-Label Non-Inferiority Randomized Controlled Trial

Trials
MedicinePharmacology
2019English

A Multi-National, Randomised, Open-Label, Parallel, Phase III Non-Inferiority Study Comparing NK105 and Paclitaxel in Metastatic or Recurrent Breast Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2019English

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

Antiviral Therapy
Infectious DiseasesPharmacology
2013English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics
Pharmacology
2016English

Dihydroartemisinin-Piperaquine Versus Chloroquine to Treat Vivax Malaria in Afghanistan: An Open Randomized, Non-Inferiority, Trial

Malaria Journal
ParasitologyInfectious Diseases
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy